Compare WRAP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRAP | MGNX |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 115.8M |
| IPO Year | 2017 | 2013 |
| Metric | WRAP | MGNX |
|---|---|---|
| Price | $1.72 | $1.71 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 371.5K | ★ 725.3K |
| Earning Date | 02-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,507,000.00 | ★ $149,962,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 155.26 |
| 52 Week Low | $1.20 | $0.99 |
| 52 Week High | $3.23 | $2.78 |
| Indicator | WRAP | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 47.47 |
| Support Level | $1.68 | $1.68 |
| Resistance Level | $1.84 | $1.74 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 24.47 | 24.39 |
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel worldwide. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.